Glofitamab and epcoritamab for large B cell lymphoma: a real-world retrospective UK analysis of efficacy, tolerability, and impact of treatment sequencing

Glofitamab and epcoritamab are CD3xCD20 bispecific antibodies licensed for relapsed/refractory large B cell lymphoma (RR LBCL), yet real-world data are limited. Data were collected from 332 patients (219 glofitamab, 113 epcoritamab) across 34 UK centres (November 2023-May 2025). This high-risk coho...

詳細記述

書誌詳細

主要な著者:	Wendy Osborne, Euan Haynes, William Wilson, Kushani Ediriwickrema, James Paterson, Tobias Menne, Dima El-Sharkawi, Li Yuan Chan, Sunil Iyengar, Andrew J. Davies, Hwai Jing Hiew, Edward Kanfer, David Foldes, Sridhar Chaganti, Henry Crosland, Mary Owen, George Follows, Anna Santarsieri, Sarah Lawless, Matthew Wilson, Pam McKay, Robert Osborn, David Tucker, Cristina M. Thiebaud, Christopher P. Fox, Harriet Ambrose, Mary Gleeson, Jeff Lam, Angus Broom, Jeffery Smith, Matthew Wells, Laura Oldham, Kim Linton, Lisa Jeffers, Andrea Kuhnl, Graham Collins, Janine Qasim, Nimish Shah, Rory McCulloch, Mahina Baloch, Catherine Cox, David Lewis, Abigail Martin, Kyaw Zin Dino Maw, Jane Norman, Vismay Deshani, Victoria Stables, Gavin Preston, Dominic Culligan, John Willan, Matthew Ahearne, Rishabh Motiwale, Laura Dunning, Joanna Fawcett, Philippa Kelsey, Caroline Besley, Sanne Lugthart, Jack Easton, Sudarshan Gurung, Desmond Ojie, Susanna Mathew, Rebecca Auer, William Townsend
フォーマット:	Artigo
言語:	Inglês
出版事項:	Ferrata Storti Foundation 2026-05-01
シリーズ:	Haematologica
オンライン･アクセス:	https://haematologica.org/article/view/14177
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!